Age progression from vicenarians (20 –29 year) to nonagenarians (90–99 year) among a population pharmacokinetic/pharmacodynamic (PopPk-PD) covariate analysis of propofol-bispectral index (BIS) electroencephalography

ConclusionWe quantified and graded EEG-BIS age-progression among different age groups divided by decades. We demonstrated deeper BIS values with decades ’ age progression. Our data has important implications for propofol dosing. The practical information for physicians in their daily clinical practice is using propofol Cp of 3.5  μg mL−1 might not yield BIS value of 50 in elderly patients. Our simulations showed that the recommended regimen of Cp 3.5  μg mL−1 for 20 –29 year should be gradually decreased to 2.0 μg mL−1 for 80 –89 year.Clinical trial registry numbersEuropean Community Clinical Trials Database EudraCT (http://eudract.emea.eu) initial trial registration number: 2011-002847-81, and subsequently registered atwww.clinicaltrials.gov; trial registration number: NCT02585284. Xijing Hospital of Fourth Military Medical University ethics committee approval number 20110707-4.
Source: Journal of Pharmacokinetics and Pharmacodynamics - Category: Drugs & Pharmacology Source Type: research